Die Pressemitteilungen werden von der FUJIFILM Corporation in Japan herausgegeben.
Fujifilm kann nicht versichern, dass die von diesen Mitteilungen betroffenen Artikel in allen Ländern und Teilen dieser Welt käuflich erwerbbar sind.
Bitte beachten Sie, dass der Inhalt dieser Website zum Zeitpunkt der Pressemitteilung als solcher Gültigkeit hat und ohne vorherige Ankündigung geändert werden kann. Die in der jeweiligen Mitteilung veröffentlichten Informationen, einschließlich der Verfügbarkeit von Artikeln, Spezifikationen, Preise und Kontakte, sind die zum Zeitpunkt der Veröffentlichung geltenden.
- Apr 12, 2024
- Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina
- Feb 29, 2024
- FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
- Dez 5, 2023
- Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
- Nov 8, 2023
- FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility
- Jun 6, 2023
- Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services
- Mär 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Dez 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Dez 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Okt 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Jun 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Apr 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Mär 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product - Jan 26, 2022
- Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Sep 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Aug 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
- Jun 29, 2021
- $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
- Jun 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical)